Current Status of Drug Delivery Systems for Antifungal Drugs

DOI IR IR (HANDLE) Web Site 2 Citations 39 References
  • Izumikawa Koichi
    Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences
  • Kohno Shigeru
    Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences

Bibliographic Information

Other Title
  • 深在性真菌症に対するDDS
  • シンザイセイ シンキンショウ ニ タイスル DDS

Search this article

Description

The number of deep-seated mycosis cases is increasing rapidly along with the extreme advanced technology and highly sophisticated treatment. High mortality of deep-seated mycosis is critical concern, and an appropriate strategy and usage of antifungals is extremely important. The increasing potential efficacy of antifungals using the technology of drug delivery system is one of the reasonable strategies for improving the outcome of these patients with fungal infection. The development of liposomal amphotericin B using liposome is considered as a successful model case of development of newer drugs to improve the potential antifungal activity and reduce the cytotoxic effect using drug delivery system. Other newer antifungal drugs using a variety of drug delivery technology are currently being developed and numerous studies are underway. The main aim of this review is to introduce these developing drugs and the future of management of deep-seated mycosis.

Journal

  • Drug Delivery System

    Drug Delivery System 27 (2), 93-105, 2012

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

Citations (2)*help

See more

References(39)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top